ERBB2 and breast cancer: p38 MAPK signaling has been shown to promote tumor growth (Voisset et al., 2013), and enhanced p38 MAPK phosphorylation has been correlated with poor overall survival in patients with HER-2 negative breast cancer (Esteva et al., 2004) or with HCC (Wang et al., 2012).